Topical tacalcitol as neoadjuvant for photodynamic therapy of acral actinic keratoses: An intra-patient randomized study

Borgia, Francesco; Riso, Gabriella; Catalano, Fabio; Coppola, Marialorena; Giuffrida, Roberta; Cannavò, Serafinella Patrizia

doi:10.1016/j.pdpdt.2020.101803

Cited by 8 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, owing to its high tolerability, the use of tirbanibulin could be considered for the simultaneous treatment of several areas of 25cm 2 to treat a larger field of cancerization simultaneously. Furthermore, to treat more hyperkeratotic lesions (Olsen grade 3), a possible pre-treatment with salicylic acid or keratoregulators derived from vitamin D could be evaluated to reduce the thickness of the keratotic component, thus ensuring that tirbanibulin can carry out its therapeutic effect [43].…”

Section: Discussionmentioning

confidence: 99%

Tirbanibulin 1% Ointment for Actinic Keratosis: Results from a Real-Life Study

Li Pomi,

Vaccaro,

Pallio

et al. 2024

Medicina

Self Cite

View full text Add to dashboard Cite

Background and Objectives: Tirbanibulin 1% ointment is a novel synthetic anti-proliferative agent that inhibits tubulin polymerization. It is approved for treating actinic keratosis (AK) on the face and scalp in adults. It has demonstrated good efficacy, an adequate safety profile and excellent patient adherence in the phase 3 clinical trials, however data about its real-life efficacy and safety are lacking. Here we report the experience of the dermatology unit of the University Hospital of Messina. Materials and Methods: We performed a spontaneous open-label, prospective non-randomized study to assess the effectiveness and safety of tirbanibulin 1% ointment for the treatment of 228 AKs in 38 consecutive patients—28 males (73%) and 10 females (26%)—aged between 52 and 92 years (mean age: 72 ± 8.92 years). Results: Total clearance was recorded in 51% of lesions, while partial clearance was recorded in 73% of lesions. An excellent tolerability profile and high compliance rate were observed, with no treatment discontinuation due to the onset of adverse events. Conclusion: Our real-life experience confirms the effectiveness and safety of tirbanibulin ointment for the treatment of AKs.

show abstract

Section: Discussionmentioning

confidence: 99%

Tirbanibulin 1% Ointment for Actinic Keratosis: Results from a Real-Life Study

Li Pomi,

Vaccaro,

Pallio

et al. 2024

Medicina

Self Cite

View full text Add to dashboard Cite

show abstract

“…AK biopsies after this combination exhibited increased TSLP expression and massive CD4+ T cell infiltrates that persisted in the epidermal niche, being responsible for this preventive outcome [ 45 , 46 , 47 , 48 ]. Additionally, topical calcitriol and calcipotriol have been used previous to ALA or MAL PDT, enhancing the efficacy but also the side effects [ 49 , 50 ].…”

Section: Other Therapies Used Off-label For Actinic Keratosis and Can...mentioning

confidence: 99%

Topical Immunotherapy for Actinic Keratosis and Field Cancerization

Bernal Masferrer,

Gracia Cazaña,

Bernad Alonso

et al. 2024

Cancers

View full text Add to dashboard Cite

This comprehensive review delves into various immunotherapeutic approaches for the management of actinic keratoses (AKs), precancerous skin lesions associated with UV exposure. Although there are treatments whose main mechanism of action is immune modulation, such as imiquimod or diclofenac, other treatments, apart from their main effect on dysplastic cells, exert some immunological action, which in the end contributes to their efficacy. While treatments like 5-fluorouracil, imiquimod, photodynamic therapy, and nicotinamide are promising in the management of AKs, especially in immunocompetent individuals, their efficacy is somewhat reduced in solid organ transplant recipients due to immunosuppression. The analysis extends to optimal combination, focusing on cryoimmunotherapy as the most relevant. New immunotherapies include resimiquimod, ingenol disoxate, N-phosphonacetyl-L-aspartate (PALA), or anti-PD1 that have shown promising results, although more studies are needed in order to standardize their use.

show abstract